Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10255865 | 0.77 | NNMT (0.44) | NNMTPDE10APOLBTDP1P2RX7 | |
| SCHEMBL2608531 | 0.73 | NNMT (0.49) | NNMTPDE10APOLBTDP1P2RX7 | |
| SCHEMBL3671439 | 0.72 | APLNR (0.44) | NNMTPDE10APOLBTDP1L3MBTL1 | |
| SCHEMBL31010430 | 0.69 | NNMT (0.41) | NNMTPDE10APOLBTDP1P2RX7 | |
| SCHEMBL12701655 | 0.68 | MPI (0.46) | NNMTKMT2A | |
| SCHEMBL172558 | 0.65 | NNMT (0.52) | NNMTPDE10APOLBTDP1SIRT2 | |
| SCHEMBL4977234 | 0.64 | KDM4E (0.52) | NNMTPDE10APOLBTDP1L3MBTL1 | |
| SCHEMBL14032801 | 0.63 | NNMT (0.50) | NNMTPDE10APOLBTDP1CYP1A2 | |
| SCHEMBL29935910 | 0.63 | NNMT (0.50) | NNMTPDE10APOLBTDP1CYP1A2 | |
| SCHEMBL13865700 | 0.62 | NNMT (0.48) | NNMTPDE10APOLBTDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207198-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, AVPR1B, GNRHR | NNMT 2051/4885PDE10A 327/4885POLB 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.